GeneDx Holdings Corp. (WGS) stock
Close on Nov 10, 2026Market cap $1.64BP/E –Yield –
GeneDx Holdings Corp. grew revenue 14.6% to $460.78M over the twelve months to Sep 30, 2026. Operating income fell 1099.5% to -$99.59M, moving the operating margin from 2.5% to -21.6%. Free cash flow was -$101.22M, down 754.4% from a year earlier. At the latest close the market valued the company at $1.64B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.64B
- P/E ratio
- –
- Price to sales
- 3.55
- Price to book
- 6.68
- Dividend yield
- –
- Free cash flow yield
- -6.19%
Fundamentals
- Revenue
- $460.78M
- Net income
- -$111.05M
- EPS, diluted
- -$3.78
- Free cash flow
- -$101.22M
- Book value per share
- $8.19
- Diluted shares
- 30M
Trading
- Next earnings
- Feb 22, 2027 (estimated, before the open)
- Previous close
- $65.72
- Open
- $56.36
- Day's range
- $52.89 – $58.07
- Volume
- 3,362,009
- Average volume (20 days)
- 1,078,427
- Index membership
- Russell 2000 (since Sep 2024), Russell 3000 (since Aug 2024)
- Beta (5 years)
- 2.02
- 52-week range
- $32.21 – $170.87
- RSI (14 days)
- 37.6
- Volatility (1 year)
- 90.5%
- Relative volume
- 1.38×
- WACC
- 14.2%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 10, 2026. The S&P 500 is measured by the SPY fund.
| Period | WGS | S&P 500 | Difference | WGS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -18.6% | -3.7% | −14.9 pts | ||
| 3 months | -29.6% | -2.7% | −26.8 pts | ||
| Year to date | -57.8% | +10.8% | −68.7 pts | ||
| 1 year | -61.6% | +11.2% | −72.8 pts | ||
| 3 years | +4217.3% | +76.5% | +4140.8 pts | +250.8% | +20.8% |
| 5 years | -79.2% | +72.9% | −152.1 pts | -26.9% | +11.6% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases GeneDx filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- Results
About GeneDx
Services-Health Services
GeneDx Holdings Corp. operates as a genomics and diagnostics company focused on genetic testing services and solutions. Its offerings include diagnostic test products and diagnostic testing kits and materials, alongside technology rights and related services. The company categorizes its business operations under the GeneDx segment as well as an all other segments classification, serving third-party insurance payors, institutional customers, and self-pay individuals.
Company profile, executives and historyGeneDx stock: common questions
What is GeneDx's stock price?
WGS closed at $54.83 on Nov 10, 2026, down 16.57% on the day. Over the past 52 weeks it traded between $32.21 and $170.87.
What is GeneDx's market cap?
GeneDx was worth $1.64B at the close on Nov 10, 2026: the share price times the diluted shares outstanding.
What is WGS's P/E ratio?
GeneDx lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.78), so it has no meaningful P/E ratio.
How much revenue does GeneDx make?
GeneDx reported revenue of $460.78M for the twelve months to Sep 30, 2026, up 14.6% from a year earlier.
Does GeneDx pay a dividend?
No. GeneDx has not paid a cash dividend over the last twelve months.
When does GeneDx report earnings next?
GeneDx is expected to report Q4 FY2026 results on Feb 22, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has WGS stock performed over the past year?
Including dividends, WGS returned -61.6% over the past year, against +11.2% for the S&P 500.
Who are GeneDx's competitors?
Companies most similar to GeneDx by business, industry and size include DCGO, CDNA, VCYT, USPH, FLGT.
See a number that looks wrong?